Parabacteroides goldsteinii as Next Generation Probiotics
Background P. goldsteinii for Anti-Obesity Highlights Products FAQs Resources
Introduction to Parabacteroides goldsteinii
Parabacteroides goldsteinii has exhibited great potential to be a probiotic against obesity. Creative Biolabs here provides high-quality custom Parabacteroides goldsteinii-based probiotic development services for worldwide clients.
Introduction to Parabacteroides goldsteinii
Parabacteroides goldsteinii (P. goldsteinii), is a Gram-negative bacterium belonging to the genus of Parabacteroides and the family of Porphyromonadaceae. It was formerly named as Bacteroides goldsteinii, a human pathogen isolated from clinical intestinal specimens by Song et al. in 2005, and latterly reclassified as P. goldsteinii comb. nov. by Sakamoto et al. in 2006.
P. goldsteinii is a non-spore-forming and non-motile bacterium with rod-shaped and about 0.9-1.5 μm×1.2-10 μm in size. Colonies on the Brucella blood agar presents opaque gray round, slightly convex and smooth, with a diameter of 1~2 mm. P. goldsteinii is an obligately anaerobic species novel species principally distributing in human intestinal and feces.
Probiotic Potential of P. goldsteinii for Anti-Obesity
Although P. goldsteinii was identified as a pathogen from individuals with clinical infections, its probiotic potential against obesity has been demonstrated in high-fat diet-induced obesity mice. During the study of anti-obesogenic effects of Hirsutella sinensis (H. sinensis), gut microbiota analysis found that the level of P. goldsteinii is significantly reduced in obesity mice, while is much higher in H. sinensis treated mice. Besides, further investigations indicated that:
-
Firstly, oral administration of live P. goldsteinii significantly reduced the weight gain and visceral fat, maintained intestinal integrity, and increased adipose tissue thermogenesis, exhibiting therapeutic effects on obesity and metabolic disorders in obesity mice model;
-
Secondly, the live P. goldsteini treatment reduced endotoxemia and inflammation through inhibiting the mRNA expression of IL-1β and cell monolayer disruption, meanwhile, increasing the expression of IL-10 and ZO-1 in the colon;
-
Thirdly, efficient transfer of P. goldsteinii by horizontal fecal microbiota transplantation also reduced insulin resistance and symptoms of nonalcoholic fatty liver disease in high-fat diet mice;
-
Lastly and importantly, all these effective treatments by live P. goldsteini had no impact on liver or kidney functions.
Fig.1 Proposed model for the anti-obesogenic effects of Hirsutella sinensis mycelium and P. goldsteinii in high-fat diet-fed mice. 1
For Live Biotherapeutics Research, Choose Creative Biolabs!
Probiotics-based live biotherapeutic has emerged as a novel, safe, and effective alternative for multiple disease treatment. As an experienced biotechnology company in innovative drug discovery, Creative Biolabs has invested numerous energy and efforts in the development of Next-Generation probiotics. In addition to P. goldsteini, we provide a variety of probiotic species development services for the treatment of related diseases based on:
-
Advanced and special-constructed Platform
-
Highly experienced scientists and staff specialized in live biotherapeutics
-
Highly customized service according to different research demand
-
Streamlined services from consultation and project design, to on-time delivery and data interpretation
Please feel free to contact us and our experienced technicians will give you the most detailed answers to your questions.
P. goldsteinii Related Products at Creative Biolabs
Related Products
|
CAT
|
Product Name
|
Product Overview
|
|
LBST-040FG
|
Parabacteroides goldsteinii; Human abdominal fluid
|
Parabacteroides goldsteinii was isolated from human abdominal fluid. It is a Gram-negative, obligately anaerobic non-spore-forming and non-motile bacterium.
|
|
LBST-041FG
|
Parabacteroides goldsteinii; 63736
|
Parabacteroides goldsteinii was isolated from human. It is a Gram-negative, obligately anaerobic non-spore-forming and non-motile bacterium.
|
|
LBST-042FG
|
Parabacteroides goldsteinii; 74546
|
Parabacteroides goldsteinii was isolated from human wound. It is a Gram-negative, obligately anaerobic non-spore-forming and non-motile bacterium.
|
|
LBST-043FG
|
Parabacteroides goldsteinii; 29187
|
Parabacteroides goldsteinii was isolated from caecal content. It is a Gram-negative, obligately anaerobic non-spore-forming and non-motile bacterium.
|
|
LBST-044FG
|
Parabacteroides goldsteinii; 19448
|
Parabacteroides goldsteinii was isolated from human tissue. It is a Gram-negative, obligately anaerobic non-spore-forming and non-motile bacterium.
|
|
LBST-045FG
|
Parabacteroides goldsteinii; 342457
|
Parabacteroides goldsteinii is a Gram-negative, obligately anaerobic non-spore-forming and non-motile bacterium from the genus of Parabacteroides.
|
FAQs
What unique advantages does P. goldsteinii offer in probiotic formulations for metabolic health?
P. goldsteinii stands out due to its robust influence on reducing obesity-related markers and improving metabolic health in animal studies. This includes significant reductions in body weight, fat accumulation, and insulin resistance. These properties make it a promising candidate for inclusion in probiotic formulations aimed at managing metabolic syndrome and related disorders, showcasing the potential of tailored probiotic therapies to address specific health concerns.
How does the inclusion of P. goldsteinii enhance probiotic blends for gastrointestinal health?
The inclusion of P. goldsteinii in probiotic blends enhances gastrointestinal health by stabilizing gut microbiota and reducing inflammation. Its efficacy in experimental models of colitis and its ability to improve symptoms of inflammatory bowel disease illustrate its potential as a key component in next-generation probiotic products designed for gut health and the management of digestive disorders.
In what ways does Creative Biolabs' development of P. goldsteinii-based products stand out in the biotech industry?
Creative Biolabs distinguishes itself in the biotech industry by leveraging advanced, specialized platforms and a team of experienced scientists to develop P. goldsteinii-based products. Their approach ensures that each probiotic product is not only effective but also tailored to meet specific research and clinical needs. This focus on customization and quality positions their probiotics at the forefront of therapeutic innovations.
What research has been done on the safety and tolerability of P. goldsteinii?
Research confirms that P. goldsteinii is generally well-tolerated with no adverse effects on liver or kidney function in animal models. Ongoing studies are essential to fully understand its safety profile, especially in human clinical trials, to ensure its efficacy and safety as a therapeutic probiotic.
Resources
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
